4.8 Article

Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1105419108

关键词

immune dominance; T-cell repertoire; T-cell differentiation; T-cell function

资金

  1. Wilhelm Sander Foundation
  2. Swiss National Center of Competence in Research Molecular Oncology
  3. Ludwig Institute for Cancer Research
  4. Swiss National Science Foundation [3200B0-118123]

向作者/读者索取更多资源

Immune protection from infectious diseases and cancer is mediated by individual T cells of different clonal origin. Their functions are tightly regulated but not yet fully characterized. Understanding the contribution of each T cell will improve the prediction of immune protection based on laboratory assessment of T-cell responses. Here we developed techniques for simultaneous molecular and functional assessment of single CD8 T cells directly ex vivo. We studied two groups of patients with melanoma after vaccination with two closely related tumor antigenic peptides. Vaccination induced T cells with strong memory and effector functions, as found in virtually all T cells of the first patient group, and fractions of T cells in the second group. Interestingly, high functionality was not restricted to dominant clonotypes. Rather, dominant and nondominant clonotypes acquired equal functional competence. In parallel, this was also found for EBV- and CMV-specific T cells. Thus, the nondominant clonotypes may contribute similarly to immunity as their dominant counterparts.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Rebecca J. Lee, Oskar Wysocki, Cong Zhou, Rohan Shotton, Ann Tivey, Louise Lever, Joshua Woodcock, Laurence Albiges, Angelos Angelakas, Dirk Arnold, Theingi Aung, Kathryn Banfill, Mark Baxter, Fabrice Barlesi, Arnaud Bayle, Benjamin Besse, Talvinder Bhogal, Hayley Boyce, Fiona Britton, Antonio Calles, Luis Castelo-Branco, Ellen Copson, Adina E. Croitoru, Sourbha S. Dani, Elena Dickens, Leonie Eastlake, Paul Fitzpatrick, Stephanie Foulon, Henrik Frederiksen, Hannah Frost, Sarju Ganatra, Spyridon Gennatas, Andreas Glenthoj, Fabio Gomes, Donna M. Graham, Christina Hague, Kevin Harrington, Michelle Harrison, Laura Horsley, Richard Hoskins, Prerana Huddar, Zoe Hudson, Lasse H. Jakobsen, Nalinie Joharatnam-Hogan, Sam Khan, Umair T. Khan, Khurum Khan, Christophe Massard, Alec Maynard, Hayley McKenzie, Olivier Michielin, Anne C. Mosenthal, Berta Obispo, Rushin Patel, George Pentheroudakis, Solange Peters, Kimberly Rieger-Christ, Timothy Robinson, Jacobo Rogado, Emanuela Romano, Michael Rowe, Marina Sekacheva, Roseleen Sheehan, Julie Stevenson, Alexander Stockdale, Anne Thomas, Lance Turtle, David Vinal, Jamie Weaver, Sophie Williams, Caroline Wilson, Carlo Palmieri, Donal Landers, Timothy Cooksley, Caroline Dive, Andre Freitas, Anne C. Armstrong

Summary: The study aimed to develop a decision support tool to assist in hospital admission decisions and predict the severity of COVID-19 in cancer patients. The results showed that the CORONET model could effectively predict the need for hospital admission and the severity of the disease, and it was validated in healthcare systems worldwide.

JCO CLINICAL CANCER INFORMATICS (2022)

Article Oncology

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

Claus Garbe, Ulrike Keim, Teresa Amaral, Carola Berking, Thomas K. Eigentler, Lukas Flatz, Anja Gesierich, Ulrike Leiter, Rudolf Stadler, Cord Sunderkotter, Thomas Tuting, Jochen Utikal, Uwe Wollina, Lisa Zimmer, Christos C. Zouboulis, Paolo A. Ascierto, Alexander M. M. Eggermont, Jean-Jacques Grob, Axel Hauschild, Lidija Kandolf Sekulovic, Georgina Long, Jason J. Luke, Olivier Michielin, Ketty Peris, Dirk Schadendorf, John M. Kirkwood, Paul C. Lorigan

Summary: This study evaluates the survival probabilities of patients with stage I and II melanoma and finds that the melanoma-specific survival rates in the two cohorts are less favorable compared to the published AJCCv8 data.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Ute F. Roehrig, Somi Reddy Majjigapu, Pierre Vogel, Aline Reynaud, Florence Pojer, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao, Melita Irving, George Coukos, Olivier Michielin, Vincent Zoete

Summary: This study presents an extension of a highly efficient IDO1 inhibitor series, with the best compound showing strong inhibitory effects at both enzymatic and cellular levels. The research provides enzymatic inhibition data for nearly 100 new compounds and X-ray diffraction data for one compound in complex with IDO1, shedding light on the mechanisms behind the drop in activity observed in diverse haem-binding inhibitor scaffolds when extended to pocket B. These findings offer valuable insights for the future design of IDO1 inhibitors.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2022)

Letter Hematology

Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy

David Gachoud, Claire Bertelli, Nathalie Rufer

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18F-FDG PET/CT and Confirmed by Biopsy

Nathalie Testart Dardel, Elsa Isenborghs, Massimo Valerio, Olivier Michielin, Niklaus Schaefer

Summary: This case demonstrates an unusual presentation of melanoma metastasis in the right seminal vesicle, detected by F-18-FDG digital PET/CT. Histological analysis confirmed the diagnosis and the patient received stereotactic radiation therapy. The study highlights the excellent performance of state-of-the-art digital PET/CT and emphasizes the importance of a multidisciplinary approach in the treatment and follow-up of melanoma patients.

CLINICAL NUCLEAR MEDICINE (2023)

Article Chemistry, Organic

Oxidative Coupling of 4-Hydroxycoumarins with Quinoxalin-2(1H)-ones Induced by Visible Light under Aerobic Conditions

Loris Laze, Paula Romero, Irene Bosque, Jose C. Gonzalez-Gomez

Summary: This study presents an efficient method for the regioselective C-3-H/C-3-H cross-coupling of 4-hydroxycoumarin derivatives with quinoxalin-2(1H)-ones, using visible light and air as the terminal oxidant. The reaction is promoted by sunlight under mild and sustainable conditions, and the C-4-OH group at the coumarin ring is essential for the reaction and allows for diversified functionalizations of the final products. The greenness of this methodology over previous ones is demonstrated through qualitative and semi-quantitative analysis, and a plausible mechanism for this transformation is proposed through various experiments.

EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2023)

Article Oncology

Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma

Bianca Gautron Moura, Camille L. Gerard, Nathalie Testart, Marian Caikovski, Alexandre Wicky, Veronica Aedo-Lopez, Gregoire Berthod, Krisztian Homicsko, John O. Prior, Clarisse Dromain, Lana E. Kandalaft, Michel A. Cuendet, Olivier Michielin

Summary: In stage IV melanoma, the combination of ipilimumab and nivolumab significantly improves outcomes but has a major financial impact on healthcare. This study analyzes the costs associated with ipilimumab-nivolumab combination, focusing on immune-related adverse events (irAE). Surprisingly, toxicity costs are insignificant compared to the total treatment costs, and patients with higher toxicity grades have lower costs and better outcomes. These findings provide important information for clinicians and healthcare organizations making treatment decisions in immunotherapy.

CANCERS (2023)

Letter Hematology

Successful outcome of pregnancy post-allogeneic stem cell transplant despite severe RH1 alloimmunization: A case report

Mathilde Gavillet, Nathalie Rufer, Francesco Grandoni, Mattia Rizzi, Nicolas Vulliemoz, David Baud, Lorenzo Alberio, Giorgia Canellini, Helene Legardeur

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient

Sandro Anchisi, Anita Wolfer, Bettina Bisig, Edoardo Missiglia, Amine Tiab, Ehab Mohamed Kamel, Olivier Michielin, George Coukos, Krisztian Homicsko

Summary: The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors, and BRAF/MEK combination has shown further improvements. BRAF inhibitor use has also been proposed in low-grade ovarian tumors.

CANCER BIOLOGY & THERAPY (2023)

Article Biochemistry & Molecular Biology

Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

Fanny Seraphine Krebs, Bianca Moura, Edoardo Missiaglia, Veronica Aedo-Lopez, Olivier Michielin, Petros Tsantoulis, Bettina Bisig, Mounir Trimech, Vincent Zoete, Krisztian Homicsko

Summary: The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains challenging as Triple wildtype (TWT) melanomas lacking BRAF, NRAS, or NF1 mutations are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanomas and function as resistance mechanisms to BRAF inhibition. This case study illustrates the difficulties in combining MEK1 and CDK4/6 inhibitors in the presence of resistance to MEK inhibitor monotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Interactive process mining of cancer treatment sequences with melanoma real-world data

Alexandre Wicky, Roberto Gatta, Sofiya Latifyan, Rita De Micheli, Camille Gerard, Sylvain Pradervand, Olivier Michielin, Michel A. Cuendet

Summary: The increasing availability of clinical real-world data (RWD) provides an opportunity to supplement evidence from randomized clinical trials and explore treatment outcomes in real-life conditions. Process mining is a suitable methodology for analyzing treatment paths and outcomes. In this study, an interactive application was implemented to compare treatment sequences based on overall survival, progression-free survival, and best overall response. The application was used to conduct a descriptive analysis of RWD in advanced melanoma patients and explore the outcomes of different treatment choices. Results showed long-term survival benefits from immune-checkpoint inhibitors rechallenge, suggesting potential implications for treatment guidelines.

FRONTIERS IN ONCOLOGY (2023)

Meeting Abstract Medicine, General & Internal

A model of care using patient-reported outcomes for remotely managing symptoms of cancer patients treated with immune checkpoint inhibitors

A. Da Silva Lopes, S. Colomer-Lahiguera, C. Darnac S. Giacomini, A. Wicky, S. Bugeia, G. Gutknecht, N. Mederos Alfonso, S. Latifyan, A. Addeo, O. Michielin, M. Eicher

SWISS MEDICAL WEEKLY (2022)

Correction Oncology

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (vol 10, e003024, 2022)

O. Michielin, A. Lalani, C. Robert

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Health Care Sciences & Services

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma

Victoria Federico Paly, Murat Kurt, Lirong Zhang, Marcus O. Butler, Olivier Michielin, Adenike Amadi, Emma Hernlund, Helen M. Johnson, Srividya Kotapati, Andriy Moshyk, John Borrill

Summary: This study evaluated the predictive accuracy of different models in estimating the long-term overall survival benefit of immune checkpoint inhibitor combination therapy in advanced melanoma. The results showed that models explicitly incorporating survival heterogeneity provided more accurate and consistent long-term overall survival estimates.

MDM POLICY & PRACTICE (2022)

Article Oncology

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

Krisztian Homicsko, Reinhard Dummer, Christoph Hoeller, Jedd D. Wolchok, F. Stephen Hodi, James Larkin, Paolo A. Ascierto, Victoria Atkinson, Caroline Robert, Michael A. Postow, Sandra Re, David Paulucci, Darin Dobler, Olivier Michielin

Summary: This retrospective analysis examined the impact of proton pump inhibitors (PPIs) on the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma. The results showed insufficient evidence to support a meaningful association between PPI use and ICI efficacy.

CANCERS (2022)

暂无数据